| Biomarker ID | 1422 |
| PMID | 24747338 |
| Year | 2014 |
| Biomarker | Insulin-Like Growth Factor-Binding Protein 6 (IGFBP-6) |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa: (> 2 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs), Ghrelin-mediated regulation of food intake and energy homeostasis, Diabetes pathways, Myometrial relaxation and contraction pathways, FSH regulation of apoptosis |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 46 patients with PCa and 42 controls with BPH were selected for analysis |
| Senstivity | 97.62% |
| Specificity | 67.39% |
| AUC | 0.835 |
| Accuracy | TP=41; TN=31; FP=15; FN=1 |
| Level Of Significance | p<0.0001 |
| Method Used | Antibody Microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |